These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2016-000460-42 A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis 2018-01-05 bad-data
Reported results 2017-002581-51 An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria 2020-04-06 due-trials
Not reported 2019-004391-19 A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis Een ... 2022-08-05 due-trials
Completed, reported early Terminated 2022-001625-79 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately C... 2024-05-13 not-yet-due
Completed, reported early Terminated 2022-001847-26 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous U... 2024-06-06 not-yet-due